The Financial Post reports in its Saturday edition that the chorus of voices warning of risks to Aurora Cannabis's balance sheet is growing louder. The Post's Kristine Owram writes that with a $360-million loan coming due in August, 2021, at least three analysts have cautioned that the pot company may be unable to meet the covenants on that debt. "With balance sheet risks to remain a core investment thesis in 2020 in our view, and lingering uncertainty especially on financial covenants, we struggle to envision a scenario where shares have sustainable support," Bank of America analyst Christopher Carey said in a note published Friday. He downgraded Aurora to underperform from neutral and cut his 12-month price target to $1.50 from $4. Ultimately, Mr. Carey expects Aurora will be able to restructure the covenants. Aurora fell as much as 10.7 per cent Friday, and is down 83 per cent from its high in March. Piper Sandler analyst Michael Lavery also downgraded Aurora to underweight from neutral on Friday and cut his price target to $1 from $3, citing "notable risk" from its balance sheet position. Mr. Lavery cautioned that Aurora is likely to generate negative cash from operations until the fiscal third quarter of 2021.